The activity of γδ T cells against paediatric liver tumour cells and spheroids in cell culture
Article first published online: 22 OCT 2012
© 2012 John Wiley & Sons A/S
Volume 33, Issue 1, pages 127–136, January 2013
How to Cite
Hoh, A., Dewerth, A., Vogt, F., Wenz, J., Baeuerle, P. A., Warmann, S. W., Fuchs, J. and Armeanu-Ebinger, S. (2013), The activity of γδ T cells against paediatric liver tumour cells and spheroids in cell culture. Liver International, 33: 127–136. doi: 10.1111/liv.12011
- Issue published online: 10 DEC 2012
- Article first published online: 22 OCT 2012
- Accepted manuscript online: 5 OCT 2012 08:24AM EST
- Manuscript Accepted: 13 AUG 2012
- Manuscript Received: 10 APR 2012
- Faculty of Medicine
- immune therapy;
- paediatric hepatocellular carcinoma;
- therapeutic antibodies;
- γδ T cells
Chemoresistance and advanced tumour stage at time of diagnosis are the major reasons for poor treatment results in hepatoblastoma (HB) and paediatric hepatocellular carcinoma (HCC). Positive results with transplantation of liver and bone marrow revealed the impact of the immune system on the treatment of liver malignancies.
Cytotoxic-immune-cells-like natural killer (NK) and T cells are major player in the defence against developing tumours. This study aimed to specifically analyse the ability of ex-vivo expanded γδ T cells to recognise and lyse HB and HCC cell lines in coculture assays.
Cell viability after treatment with γδ T cells was evaluated with two HB (HUH6 and HepT1) and one HCC cell line (HC-AFW1) using a MTT-based cytotoxicity assay. The binding of T cells to target cells was monitored using immunofluorescence microscopy.
Incubation of hepatic tumour cell lines with γδ T cells led to a significant decrease in tumour cell viability. This was enhanced by zoledronic acid and histone deacetylase inhibitors. MT110, an EpCAM/CD3-bispecific BiTE antibody could bluntly enhance tumour cell lysis close to completion. γδ T cells efficiently interacted with HB and HCC cells in a spheroid culture model.
Bispecific antibodies such as MT110 might be used to intensify the antitumoural effect of γδ T cells in context of adoptive immune cell transfer. Optimised immunotherapeutic strategies might therefore improve the outcome of high risk hepatoblastoma and hepatocellular carcinoma.